Cargando…
Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis
BACKGROUND: Trastuzumab is currently the standard treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, it is not recommended for HER2-positive breast cancer patients during pregnancy as it may jeopardize safety of the fetus. Nevertheless, there is evidence t...
Autores principales: | Xia, Lin-Yu, Hu, Qing-Lin, Zhou, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061001/ https://www.ncbi.nlm.nih.gov/pubmed/33882925 http://dx.doi.org/10.1186/s12905-021-01301-9 |
Ejemplares similares
-
Efficacy and Safety of Radiofrequency Ablation for Breast Cancer Smaller Than 2 cm: A Systematic Review and Meta-Analysis
por: Xia, Lin-Yu, et al.
Publicado: (2021) -
The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis
por: Chen, Jiarong, et al.
Publicado: (2016) -
6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2021) -
Methodological quality evaluation of systematic reviews or meta-analysis of trastuzumab-based therapy for breast cancer: A systematic review
por: Wei, Hua, et al.
Publicado: (2021) -
Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis
por: Cobert, Amani M., et al.
Publicado: (2020)